A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Conditions:   Stage III Cutaneous Melanoma;   Stage IV Cutaneous Melanoma;   Locally Advanced Melanoma;   Locally Advanced Solid Neoplasm;   Metastatic Head and Neck Squamous Cell Carcinoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Melanoma;   Metastatic Urothelial Carcinoma;   Non-Small Cell Lung Carcinoma;   Stage IB Lung Cancer AJCC v7;   Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage III Ureter Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IV Ureter Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
Interventions:   Drug: Abexinostat;   Biological: Pembrolizumab
Sponsors:   Rahul Aggarwal;   Xynomic Pharmaceuticals, Inc.
Not yet recruiting

https://ift.tt/2mswQLL